SC 13G/A: FENNEC PHARMACEUTICALS INC.

AI Summary

SC 13G/A filing by FENNEC PHARMACEUTICALS INC..

Risk Assessment

Risk Level: low

FAQ

Filing Documents

• formsc13ga.htm (SC 13G/A) — 157KB
• 0001493152-24-044914.txt ( ) — 159KB

From the Filing

SC 13G/A 1 formsc13ga.htm UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* FENNEC PHARMACEUTICALS INC. Common Shares (Title of Class of Securities) 31447P100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 31447P100 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) DG Capital Management, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) (b) 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 1,522,204* 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 1,522,204* 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,522,204* 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.5%* 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA CUSIP No. 31447P100 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) DG Value Partners II Master Fund, LP 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) (b) 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 1,314,903* 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 1,314,903* 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,314,903* 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.8%* 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN CUSIP No. 31447P100 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Dov Gertzulin 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) (b) 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION United NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 1,522,204* 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 1,522,204* 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,522,204* 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.5%* 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN, HC CUSIP No. 31447P100 Item 1. (a). Name of Issuer: Fennec Pharmaceuticals Inc. (the “Issuer”) (b). Address of issuer’s principal executive offices: PO Box 13628, 68 TW Alexander Drive Research Triangle Park, NC 27709 Item 2. (a). Name of person filing: DG Capital Management, LLC* DG Value Partners II Master Fund, LP* Dov Gertzulin* (b). Address or principal business office or, if none, residence: 460 Park Avenue, 22nd Floor New York, NY 10022 (c). Citizenship: DG Capital Management, LLC – Delaware, USA DG Value Partners II Master Fund, LP – Cayman Islands Dov Gertzulin – United States (d). Title of class of securities: Common Shares (e). CUSIP No.: 31447P100 CUSIP No. 31447P100 Item 3. If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a: N/A Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: DG Capital Management, LLC: 1,522,204* DG Value Partners II Master Fund, LP: 1,314,903* Dov Gertzulin– 1,522,204* (b) Percent of class: DG Capital Management, LLC: 5.5%* DG Value Partners II Master Fund, LP: 4.8%* Dov Gertzulin: 5.5%* (c) Number of shares as to which the person has: (i) Sole p

View Full Filing

View this SC 13G/A filing on SEC EDGAR